Form 483 Field Guide: FDA Follow-Up for Life Sciences Manufacturers
October 15, 2026 | 12:00PM–1:30PM ET | Live Webinar
Overview
Form 483 observations remain a critical focus for drug, biologic, and medical device manufacturers preparing for FDA inspections and addressing compliance concerns. This webinar will explore current 483 trends, response strategies, and common pitfalls, along with insights from FDA’s recent draft guidance on responding to Form 483 observations for human and animal drug and biologic manufacturers. Join our panel of experts for practical guidance on developing effective 483 responses and strengthening inspection readiness.
Speakers
FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals also may be honored by other states. The CLE credits will be posted as they are granted and registrants can request to be notified when approval is received.





